cas 35251-84-4|| where to buy Pyrido[3,4-b]pyrazine-2,3(1H,4H)-dione

Nom du produit:Pyrido[3,4-b]pyrazine-2,3(1H,4H)-dione

IUPAC Name:1H,2H,3H,4H-pyrido[3,4-b]pyrazine-2,3-dione

Unité d'emballage	Stock disponible	Prix($)
CM214023-1g	in stock	ȌƋ
CM214023-5g	1-2 Weeks	Ʊǧǧ
CM214023-25g	1-2 Weeks	ſƋƙ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 35251-84-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:35251-84-4; Formule moléculaire:C7H5N3O2; Point de fusion:-; Code SMILES:O=C1NC=2C=NC=CC2NC1=O; Densité:

: Numéro de catalogue:CM214023; Poids moléculaire:163.14; Point d'ébullition:; N° Mdl:MFCD01411816; Stockage:

: Quinazolines; Quinazolines belong to heterocyclic chemistry, also known as 1,3-naphthalenes. The backbone consists of two six-membered aromatic rings fused to each other, with two nitrogen atoms at positions 1 and 3 on the backbone. The presence of these two nitrogen atoms in quinazoline increases its importance in pharmaceutical and biological reactions. Quinazolines and their derivatives are among the most important heterocyclic compounds due to their diverse chemical reactivity and important range of biological activities.

: CVN424; In a Phase 2 clinical trial, CVN424, a novel, non-dopaminergic, GPR6 inverse agonist, demonstrated a significant reduction in OFF time and was safe and well tolerated with low rates of mostly mild and moderate adverse events. Patients also reported enhanced motor functionality in daily activities, as assessed by the UPDRS Part II. These findings enhance the confidence in CVN424's potential to address both motor and non-motor symptoms of Parkinson’s disease, consistent with observations in pre-clinical models, potentially heralding a transformative non-dopaminergic therapy.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.